


## Highly Specialised Technologies Evaluation Committee Interests Register Topic [ID4056]

Publication Date: 26/07/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Emtiyaz Chowdhury	Committee Member	Non-financial professional	He is employed by Parexel who provides services to the manufacturer. He has not been involved in any specific activities related to the technology under	28/02/2023		It was agreed that his declaration would not prevent Emtiyaz from participating in discussions on this evaluation.
Dr Prithwiraj Das	Committee	Non-financial	consideration.  He works in pharmaceutical	02/03/2023		It was agreed that his
	Member	professional	market access as Founding Director of G2PR Ltd. He has not worked on these products, indications, or possible comparators in the past.			declaration would not prevent Dr Das from participating in discussions on this evaluation.
Dominic Pivonka	Committee Member	Financial	His employer (AbbVie) has treatments in development (Phase 1-3) for non-small-cell lung cancer including one that has been selected for appraisal through the NICE	22/02/2023		It was agreed that his declaration would not prevent Dominic from participating in



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			technology appraisals process (Telisotuzumab vedotin). This treatment is for c-MET overexpressed, EGFR wild-type, which is not in the same target population as the indication for selpercatinib, and so not a possible competitor or comparator.			discussions on this evaluation.
Dr Shobhit Baijal	Clinical Expert	Financial	He has received honoraria from Lilly and Roche (who make pralsetinib) for consultancy work.	26/08/2022 15/03/2023		It was agreed that his declaration would not prevent Dr Baijal from providing expert advice to the committee.